COVID-19 Infection and Parkinsonism: Is There a Link?
Parkinson’s Disease Costs Europe €22.8 Billion A Year As Cases Rise – COIN-Eu Study
September 2, 2026
The annual societal cost of Parkinson's disease across Europe reached €22.8 billion in 2019 according to a new study within the EAN-led Cost of Illness in Neurology in Europe (COIN-Eu) initiative.
First EAN Annual Report Reviews Major Milestones of 2025
August 7, 2026
Latest Posts
-
-
Breaking newsCOVID-19
Neurology and neuropsychiatry of COVID-19: a systematic review and meta-analysis of the early literature reveals frequent CNS manifestations and key emerging narratives
July 1, 2021Neurology and neuropsychiatry of COVID-19: a systematic review and meta-analysis of the early literature reveals frequent CNS manifestations and key emerging narratives -
Breaking newsCOVID-19
The prevalence of COVID-19 infection in patients with multiple sclerosis (MS): a systematic review and meta-analysis
July 1, 2021The prevalence of COVID-19 infection in patients with multiple sclerosis (MS): a systematic review and meta-analysis -
Breaking newsCOVID-19
COVID-19 associated brain/spinal cord lesions and leptomeningeal enhancement: A meta-analysis of the relationship to CSF SARS-CoV-2
July 1, 2021COVID-19 associated brain/spinal cord lesions and leptomeningeal enhancement: A meta-analysis of the relationship to CSF SARS-CoV-2 -
Breaking newsCOVID-19
Clinical review of cerebral venous thrombosis in the context of COVID-19 vaccinations: Evaluation, management, and scientific questions
July 1, 2021Clinical review of cerebral venous thrombosis in the context of COVID-19 vaccinations: Evaluation, management, and scientific questions -
Breaking newsCOVID-19
Cerebrospinal fluid from COVID-19 patients with olfactory/gustatory dysfunction: A review
July 1, 2021Cerebrospinal fluid from COVID-19 patients with olfactory/gustatory dysfunction: A review -
Breaking newsCOVID-19
Heterogeneity in Regional Damage Detected by Neuroimaging and Neuropathological Studies in Older Adults With COVID-19: A Cognitive-Neuroscience Systematic Review to Inform the Long-Term Impact of the Virus on Neurocognitive Trajectories
July 1, 2021Heterogeneity in Regional Damage Detected by Neuroimaging and Neuropathological Studies in Older Adults With COVID-19: A Cognitive-Neuroscience Systematic Review to Inform the Long-Term Impact of the Virus on Neurocognitive Trajectories -
Breaking newsCOVID-19
Systematic Review of Cases of Acute Myelitis in Individuals with COVID-19
July 1, 2021Systematic Review of Cases of Acute Myelitis in Individuals with COVID-19 -
Breaking newsCOVID-19
Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival
July 1, 2021COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival -
Breaking newsCOVID-19
Persistent visual dysfunction following PRES due to COVID-19: Case series and literature review
July 1, 2021Persistent visual dysfunction following PRES due to COVID-19: Case series and literature review -
Breaking newsCOVID-19
Risk and outcomes of COVID-19 in patients with multiple sclerosis
July 1, 2021Risk and outcomes of COVID-19 in patients with multiple sclerosis -
Breaking newsCOVID-19
Predictive factors of smell recovery in a clinical series of 288 COVID-19 patients with olfactory dysfunction
July 1, 2021Predictive factors of smell recovery in a clinical series of 288 COVID-19 patients with olfactory dysfunction -
Guillain-Barré syndrome following ChAdOx1-S/nCoV-19 vaccine
-
Breaking newsCOVID-19
Guillain-Barré syndrome variant occurring after SARS-CoV-2 vaccination
July 1, 2021Guillain-Barré syndrome variant occurring after SARS-CoV-2 vaccination -
Skeletal Muscle and Peripheral Nerve Histopathology in COVID-19









